Skin and oral lesions associated to imatinib mesylate therapy

dc.creatorBASSO, Fernanda Goncalves
dc.creatorBOER, Camila Cominato
dc.creatorCORREA, Maria Elvira Pizzigatti
dc.creatorTORREZAN, Marcia
dc.creatorCINTRA, Maria Leticia
dc.creatorMAGALHAES, Marina H. C. Gallottini de
dc.creatorSANTOS, Paulo da Silva
dc.creatorSOUZA, Carmino Antonio de
dc.date.accessioned2012-10-19T23:40:03Z
dc.date.accessioned2018-07-04T15:19:48Z
dc.date.available2012-10-19T23:40:03Z
dc.date.available2018-07-04T15:19:48Z
dc.date.created2012-10-19T23:40:03Z
dc.date.issued2009
dc.identifierSUPPORTIVE CARE IN CANCER, v.17, n.4, p.465-468, 2009
dc.identifier0941-4355
dc.identifierhttp://producao.usp.br/handle/BDPI/24936
dc.identifier10.1007/s00520-008-0536-8
dc.identifierhttp://dx.doi.org/10.1007/s00520-008-0536-8
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1621662
dc.description.abstractImatinib mesylate is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) throughout all the phases of the disease. In most cases, this drug is well tolerated; however, some cases experience side effects. Skin rashes and oral lesions are uncommon and appear to be dose-dependent. The authors report two cases of CML Ph(+) in chronic phase patients who presented skin and oral lesions probably induced by imatinib therapy.
dc.languageeng
dc.publisherSPRINGER
dc.relationSupportive Care in Cancer
dc.rightsCopyright SPRINGER
dc.rightsrestrictedAccess
dc.subjectImatinib mesylate
dc.subjectOral lesions
dc.subjectSkin lesions
dc.subjectSide effects
dc.titleSkin and oral lesions associated to imatinib mesylate therapy
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución